Xinyu Zhu

Xinyu Zhu

Auto-generated profile, based on publicly available information

Xinyu Zhu

Department of Molecular Genetics and Microbiology, Duke University School of Medicine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2022 in Science Signaling
Verified
Journal Article
Open access
TYTomer M. Yaron
Tomer M. Yaron
BHBrook E. Heaton
Brook E. Heaton
TLTyler M. Levy
Tyler M. Levy
JJJared L. Johnson
Jared L. Johnson
TJTristan X. Jordan
Tristan X. Jordan
NHNicholas Heaton
Nicholas Heaton
Multiple coronaviruses have emerged independently in the past 20 years that cause lethal human diseases. Although vaccine development targeting these viruses has been accelerated substantially, there remain patients requiring treatment who cannot be vaccinated or who experience breakthrough infections. Understanding the common host factors necessary for the life cycles of coronaviruses may reveal conserved therapeutic targets. Here, we used the known substrate specificities of mammalian protein kinases to deconvolute the sequence of phosphorylation events mediated by three host protein kinase families (SRPK, GSK-3, and CK1) that coordinately phosphorylate a cluster of serine and threonine residues in the viral N protein, which is required for viral replication. We also showed that loss or inhibition of SRPK1/2, which we propose initiates the N protein phosphorylation cascade, compromised the viral replication cycle. Because these phosphorylation sites are highly conserved across coronaviruses, inhibitors of these protein kinases not only may have therapeutic potential against COVID-19 but also may be broadly useful against coronavirus-mediated diseases.

8 December 2017 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
YHYaping Han
Yaping Han
XLXue‐Song Li
Xue‐Song Li
XZXin‐Yu Zhu
Xin‐Yu Zhu
ZSZhou Sun
Zhou Sun
MLMing Li
Ming Li
YLYong‐Min Liang
Yong‐Min Liang

1 January 2020 in Integrative Cancer Therapies
Verified
Journal Article
Open access
PDF file
JOJunwen Ou
Junwen Ou
XZXinyu Zhu
Xinyu Zhu
Hong-yu ZhangHong-yu Zhang
Hong-yu Zhang
YDYanping Du
Yanping Du
PCPengfei Chen
Pengfei Chen
CPClifford L. K. Pang
Clifford L. K. Pang
Background: This is a retrospective study to examine the effect of chemotherapy with or without intravenous vitamin C (IVC) on women with advanced triple-negative breast cancer (TNBC). Methods: From 2008 to 2016, a total of 113 patients with pathologically confirmed TNBC at Clifford Hospital were evaluated, and 70 patients were matched and divided into IVC (treatment group) and non-IVC groups (control group). The match was according to age, menopausal status, and metastatic sites. In the control group, 35 patients received gemcitabine and carboplatin. In the treatment group, 35 patients received the same chemotherapy plus IVC. Results: Baseline characteristics were not significantly different between the 2 groups. According to the criteria of RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), enhanced computed tomography scan was compared after 2 cycles of chemotherapy. In the treatment group, 2/35 cases had a complete remission (CR), 15/35 cases had partial remission (PR), and 13/35 cases had stable disease (SD). The response rate was 48.6%. In the control group, there were no CR cases, 14/35 cases had PR, 14/35 cases had SD, and the response rate was 40.0% (P > .05). The median progression-free survival time and median overall survival time was 7 months (95% confidence interval [CI] =1.5-28.5 months) and 27 months (95% CI = 4-40 months) in the treatment group compared with 4.5 months (95% CI = 1.5-8 months) and 18 months (95% CI = 3-26 months) in the control group (P < .05). All patients experienced diverse reactions in the gastrointestinal tract and myelosuppression. The incidence of adverse reactions in the treatment group was significantly lower than that of the control group (P < .05). Conclusion: IVC may have an effect on improving the prognosis of patients with advanced TNBC.

3 March 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
XZXinyu Zhu
Xinyu Zhu
SNSatoko Nakano
Satoko Nakano
VRVishwas N. Rao
Vishwas N. Rao
HMHector A. Miranda
Hector A. Miranda
MSM. Ariel Spurrier
M. Ariel Spurrier
NHNicholas Heaton
Nicholas Heaton
Sialic acid is an abundant terminal glycan found on the surface of almost all mammalian cells and is utilized by many viruses as an attachment factor and/or bona fide receptor. Altering canonical cellular glycosylation can affect the ability of viruses to initiate infections; however, no systematic analysis of the effects of altering expression of glycan “capping” enzymes on viral infection rates has been previously performed. We therefore designed an arrayed CRISPR activation screen that targeted 54 glycosyltransferases known to perform terminal glycan modifications and then examined the susceptibility of 12 different viruses that rely on sialic acid receptors on the resultant cell lines. We identified two glycosyltransferases, fucosyltransferase 1 (FUT1) and galactose-3-O-sulfotransferase 2 (GAL3ST2), as capable of inhibiting a broad range of viruses when upregulated, including influenza viruses, respiroviruses, paramyxoviruses, enteroviruses, and coronaviruses. Lectin and viral particle binding assays revealed that the fucosylation and sulfation mediated by FUT1 and GAL3ST2 reduced availability of cell surface expressed α2-3 and α2-6 sialylation and impaired viral attachment during the initial entry process. Furthermore, through adeno-associated virus delivery, we confirmed the inhibitory effects of FUT1 and GAL3ST2 on influenza viruses in various cell models, including primary differentiated human airway cells. Together, our findings identify FUT1 and GAL3ST2 as host restriction factors and suggest that their therapeutic dysregulation may represent a broad-spectrum antiviral strategy.